Skip to main content
contact
About us
Pipeline
Our technology
News & media
Focus Diseases
Investors
Regulatory announcements
Events & presentations
Share information
Share quote
Share chart
Investment calculator
Historical lookup
Shareholder information
Analyst coverage & key advisers
Financials
Half year results
Annual reports
SEC filings
Governance
Executive Leadership Team
Board of directors
Governance documents
AIM Rule 26
Resources
Investor FAQs
Information request form
Investor email alerts
Investor contacts
AIM Rule 26
AIM Rule 26
LSE
NASDAQ
About us
Pipeline
Our technology
News & media
Focus Diseases
Investors
Regulatory announcements
Events & presentations
Share information
Share quote
Share chart
Investment calculator
Historical lookup
Shareholder information
Analyst coverage & key advisers
Financials
Half year results
Annual reports
SEC filings
Governance
Executive Leadership Team
Board of directors
Governance documents
AIM Rule 26
Resources
Investor FAQs
Information request form
Investor email alerts
Investor contacts
AIM Rule 26 checklist
The following information is disclosed in accordance with Rule 26 of the AIM rules:
Our technology
Directors and their biographical details
Directors’ responsibilities
Corporate Governance
Current constitutional documents and most recent admission document
Recent circulars
Annual and half-yearly reports
The Company's ordinary shares are listed on AIM, a market operated by the London Stock Exchange, under the symbol “SLN” . The Company’s American Depository Shares (ADSs) are listed on The Nasdaq Capital Market under the symbol “SLN”. One ADS represents 3 ordinary shares.
Number of shares in issue, percentage holdings of significant shareholders and percentage of shares not in public hands
Restrictions on the transfer of shares – There are no restrictions on the transfer of shares
Details of nominated adviser and other key advisers
Silence Therapeutics plc is subject to the UK City Code on Takeovers and Mergers
Silence Therapeutics plc is incorporated in the UK. Silence Therapeutics plc has laboratories in Berlin, Germany. The commercial and management HQ is in London.